SMLR - NASDAQ
Semler Scientific, Inc.
$20.33
+0.0000%Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
At a Glance
Live SnapshotSemler Scientific, Inc. Management Team
Dr. Douglas Murphy-Chutorian M.D.
Chief Executive Officer, President & Director
Compensation
$885,111
Ms. Renae Cormier
Chief Financial Officer, Principal Accounting Officer, Head of Corporation Communications & Bus. Strategy and Secretary
Compensation
$506,399
Ms. Jennifer Oliva Herrington
Chief Operating Officer
Mr. Shane Reid
Chief Technology Officer
Dr. Herbert J. Semler
Founder & Chairman Emeritus
Compensation
$41,250
Ms. Cindy Guinasso
Senior Vice President of Business Development
Semler Scientific, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.16M worth of SMLR shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
57.7K
1.16M
-1.2M
-$1.16M
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Murphy-Chutorian Douglas
Director, Officer: Ceo, Interim Cfo And Director
$1.16M
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.16M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
1 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
SMLR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | July 17, 2025 | September 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | August 23, 2024 | October 04, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 08, 2023 | October 19, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 09, 2022 | October 20, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 10, 2021 | October 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 11, 2020 | October 22, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 30, 2019 | October 02, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 31, 2018 | October 02, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 01, 2017 | October 03, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | October 21, 2016 | November 23, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.